Stake logo

AFMD

AFFIMED NV

About AFMD

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Buy US stocks in Australia starting with AFMD. Open an account and start investing today!

Market Capitalisation

$175.10M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

1.05M

High today

$1.27

Low today

$1.18

Open price

$1.27

52-week high

$5.10

52-week low

$1.03


AFMD FAQs

One share of AFFIMED NV is valued at $1.18.

The ticker symbol for AFFIMED NV is AFMD.

To buy AFMD stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in AFMD

As of 07/02/2023 AFFIMED NV has a market cap of $175M.

The AFFIMED NV 52-week high stock price is $5.10.

The AFFIMED NV 52-week low stock price is $1.03.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.